Madrigal Pharmaceuticals (MDGL)Director sold ~$1.69M
Paul A Friedman, Director at Madrigal Pharmaceuticals, sold ~$1.69M of Madrigal Pharmaceuticals shares.
- ~$1.69M
- Approx. value · 4,768 sh @ $354.06
- 218K
- Holds after · shares reported
- Traded
- Aug 12, 2025
- Filed
- Aug 13, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jul 16, 2025Insider · 2 peopleInsiders: 14 sales (~$18.6M)
- Jul 17, 2025Insider · 2 peopleInsiders: 4 sales (~$1.9M)
- Jul 18, 2025Insider · 2 peopleInsiders: 2 sales (~$840K)
- Aug 11, 2025Insider · 2 peopleInsiders: 4 sales (~$2.2M)
- Aug 12, 2025 · this disclosureInsiderDirector sold ~$1.69M of MDGL shares in the open market
What came next
- Aug 12, 2025Insider · 2 peopleInsiders: 19 sales (~$29.2M)
- Aug 13, 2025Insider · 1 personInsiders: 17 sales (~$47.8M)
- Aug 15, 2025Insider · 1 personInsiders: 6 sales (~$3.7M)
- Aug 18, 2025Insider · 1 personInsiders: 8 sales (~$480K)
- Aug 20, 2025Insider · 1 personInsiders: 5 purchases (~$7.2M)
- Nov 4, 2025Company filing · Form 8-K · ResultsReported its results
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Madrigal Pharmaceuticals
For Madrigal Pharmaceuticals, OQRO holds 9 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MDGL page.
Other recent filings by Paul A Friedman, Director
- SEC Form 4 at Madrigal Pharmaceuticals (MDGL)Aug 13, 2025
- SEC Form 4 at Madrigal Pharmaceuticals (MDGL)Aug 13, 2025
- SEC Form 4 at Madrigal Pharmaceuticals (MDGL)Aug 13, 2025
- SEC Form 4 at Madrigal Pharmaceuticals (MDGL)Aug 13, 2025
- SEC Form 4 at Madrigal Pharmaceuticals (MDGL)Aug 13, 2025
The full history of Paul A Friedman, Director is on the profile page.
How this filing works
Other disclosures at Madrigal Pharmaceuticals
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its MDGL page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
